Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NCM – Real Time Price. Currency in USD

0.80

+0.00 (0.01%)

At close: May 12, 2026, 4:00 PM EDT

30.03.2026

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –

19.03.2026

What's Behind The Drop In Reviva Pharmaceuticals Stock?

According to an SEC filing from Wednesday, Reviva will sell 6,666,667 common shares priced at $1.50 each, a move that will raise more than $10 million for the company.

19.03.2026

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warrants to purchase up to 6,666,667 shares of common stock (the "Series H Warrants"), at a combined offering price of $1.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

18.03.2026

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

29.12.2025

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Francisco, CA.

23.12.2025

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).

23.12.2025

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia

Videos

No Data

There is no data to display

Press releases

30.03.2026

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –

19.03.2026

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

18.03.2026

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

23.12.2025

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Videos

No Data

Press releases

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Videos

No Data

Press releases

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Search stocks

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Videos

No Data

Press releases

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

What's Behind The Drop In Reviva Pharmaceuticals Stock?

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Videos

No Data

Press releases

Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia